PRESENTATION

Q2 2025 — Results presentation

Q2 2025PDF · 25 pages3.7 MB


-- 1 of 25 --

nd
July 16, 2025

-- 2 of 25 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to
applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased
scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent
Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent
Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at 	www.sec.gov, 	www.jnj.com, 	www.investor.jnj.com
or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 25 --

REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize
for a broad range of indications
Immunology
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.	Neuroscience
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV
Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with
federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority
(BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S.
Department of Health and Human Services (HHS)
Infectious Diseases
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Cardiovascular/
Metabolism/Other
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration
with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals,
Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited;
AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from
Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs;
ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Oncology
UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan	Pulmonary Hypertension
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® 	is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Global Public Health
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 25 --

CEO Remarks
Sales performance and earnings review
Cash position and guidance update
Q&A
Agenda
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech
1
2
3
4

-- 5 of 25 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 25 --

7
Q2 Earnings Summary
1,2
operational sales
growth
Innovative Medicine
MedTech
Strong momentum in
Cardiovascular, Surgery and Vision
3.8%1,3
operational sales
growth
$15 	billion+
in quarterly sales
for first time
13
brands growing
double digits
6.1%1
operational sales
growth
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes an approximate (710) basis point headwind from STELARA
3 	Includes an approximate (1,170) basis point headwind from STELARA

-- 7 of 25 --

Innovative Medicine
8
10+ 	products in market
26 	approved indications
6 	products in market
14 	approved indications
5 	products in market
6 	approved indications
Oncology 	Neuroscience
Innovative Medicines: 	Innovative Medicines: 	Innovative Medicines:
Immunology

-- 8 of 25 --

MedTech
9
Addressing one of the largest unmet
needs in healthcare
Advancing the science of surgery and
pioneering what's next
Developing transformational innovations
to improve the health of patients’ eyes
Cardiovascular 	Surgery 	Vision
MedTech Innovation: 	MedTech Innovation: 	MedTech Innovation:
VARIPULSE 	Platform Dual Energy THERMOCOOL
SMARTTOUCH 	SF Catheter
Shockwave Intravascular
Lithotripsy System
OMNYPULSE
Catheter
OTTAVA
Robotic
Surgical
System
ETHICON 	4000
Surgical Stapler
ACUVUE® OASYS 1-Day Family
TECNIS Odyssey 	TECNIS PureSee
Impella® Heart
Pump Technology

-- 9 of 25 --



-- 10 of 25 --

Darren Snellgrove
Vice President,
Investor Relations

-- 11 of 25 --

% Change
Q2 2024	Q2 2025	Regional sales results 	Operational1
Reported
7.8%	7.8%	$12.6	$13.5	U.S.
(1.9)	3.3	5.2	5.4	Europe
6.2	(0.5)	1.2	1.2
Western Hemisphere
(ex U.S.)
2.4	4.4	3.5	3.6	Asia-Pacific, Africa
0.6	3.2	9.9	10.2	International
4.6%	5.8%	$22.4	$23.7	Worldwide (WW)
Dollars in billions
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded
2nd Quarter 2025 sales
12

-- 12 of 25 --

$23.7 $22.4
$6.7 $6.8
(1.8)%; 	(3.9)%1
$2.77 $2.82
Dollars in billions, except EPS
Reported %; 	Operational %1
Sales
Adjusted earnings2 	Adjusted EPS2
5.8%; 	4.6%1
GAAP earnings
$5.5 $4.7
(2.1)%
Q2 2025 	Q2 2024
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
2nd Quarter 2025 financial highlights
GAAP EPS
13
Q2 2025 	Q2 2024 	Q2 2025 	Q2 2024
Q2 2025 	Q2 2024 	Q2 2025 	Q2 2024
$2.29 $1.93
18.2% 	18.7%

-- 13 of 25 --

Immunology
$3,993
Infectious Diseases
$803
Neuroscience
$2,051
Oncology
$6,312 CVM/Other
$930
PH
$1,113
■ 	Reported growth 	■ 	Operational growth1
$15,202
4.9%, 	3.8%
WW sales $MM
Key drivers of operational performance1
• 	DARZALEX increase driven by continued strong share gains and market growth
• 	ERLEADA increase driven by continued share gains and market growth, partially offset by the
impact of Part D redesign
• 	CARVYKTI increase driven by continued share gains and capacity expansion
• 	TECVAYLI and TALVEY growth driven by ongoing launches
• 	RYBREVANT/LAZCLUZE growth driven by ongoing launch
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA due to competitive
pressures and the impact of Part D redesign
Oncology
• 	TREMFYA increase due to share gains, market growth, and launch-related inventory dynamics,
partially offset by the impact of Part D redesign
• 	SIMPONI/SIMPONI ARIA growth driven mainly by MSD3 	return of rights in Europe
• 	REMICADE increase due to favorable patient mix, market growth, and MSD3 	return of rights in
Europe, partially offset by biosimilar competition
• 	STELARA decline driven by the impact of biosimilar competition and Part D redesign
Immunology
• 	SPRAVATO growth driven by continued increased physician and patient demand
• 	CAPLYTA acquired April 2, 2025
• 	INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA decline primarily driven by the
impact of Part D redesign and unfavorable patient mix
Neuroscience
• 	OPSUMIT/OPSYNVI increase driven by market growth, inventory dynamics, and share gains,
partially offset by the impact of Part D redesign
• 	UPTRAVI increase driven by market growth and inventory dynamics partially offset by the impact
of Part D redesign
Pulmonary
Hypertension (PH)
• 	Declines across the portfolio including COVID-19 Vaccine, partially offset by EDURANT growth	Infectious Diseases
• 	XARELTO growth driven by the impact of Part D redesign and market growth partially offset
with continued share declines
Cardiovascular /
Metabolism / Other
(CVM/Other)
Adjusted operational sales2: WW: 2.4%, U.S. 5.2%, Int’l (1.6)%
Innovative Medicine highlights – 2nd quarter 2025
WW 4.9%, U.S. 7.6%, Int’l 1.0%	Reported:
WW 3.8%, U.S. 7.6%, Int’l (1.6)%	Operational1:
4.2%, 	4.0%
7.1%, 	6.2%
24.0%, 	22.3%
(16.8)%, 	(19.0)%
(15.4)%, 	(16.0)%
Strong operational growth1 of 3.8% driven primarily by Oncology and Neuroscience
15.1%, 	14.4%
14
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website 	3 	MSD: Merck, Sharp, & Dohme
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website 	Note: Values may be rounded
Stelara impacted results1 	by ~(1,170) basis points

-- 14 of 25 --

Key drivers of operational performance1
• 	Electrophysiology: Growth driven by strength in competitive mapping, new product performance
(VARIPULSE, TRUPLUSE, NUVISION, QDOT), procedure growth, and lapping of prior year inventory
dynamics in China, partially offset by competitive pressures in PFA
• 	Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP
• 	Shockwave: 	Acquired May 31, 2024
Cardiovascular
• 	Hips: 	Reflects impacts of volume-based procurement (VBP) in China, revenue disruption from the
previously announced Orthopaedics transformation, and trade inventory dynamics, partially offset by
procedure growth
• 	Trauma: 	Primarily driven by lapping of strong prior year comparator offset by recently launched products,
procedure growth, and commercial execution
• 	Knees: 	Driven by competitive pressures, market headwinds, and revenue disruption from the previously
announced Orthopaedics transformation, partially offset by strength of the ATTUNE portfolio and pull
through related to the VELYS Robotic assisted solutions
• 	Spine, Sports & Other: 	Reflects competitive pressures, price pressures in the U.S. Early Interventional
segment, revenue disruption from the previously announced Orthopaedics transformation, and VBP in
China
• 	Spine: 	~ -7% WW, ~ -4% U.S., ~ -12% Int’l
Orthopaedics
• 	Advanced
• 	Biosurgery: 	~ +7% Growth driven by continued strength of the portfolio (SURGIFLO, SURGICEL
Powder, Evarrest, and VISTASEAL) and commercial execution, partially offset by VBP in China
• 	Endocutters: 	~ +1% Increase primarily due to strategic price actions partially offset by VBP in China
and competitive pressures
• 	Energy: 	~ -6% Due to competitive pressures, Harmonic market decline in the U.S., VBP in China and
OUS tender timing, partially offset by go-to-market changes in EMEA
• 	General: 	Growth primarily due to technology penetration and upgrades within our differentiated Wound
Closure portfolio (Barbed & PLUS Sutures)
Surgery
• 	Contact Lenses/Other: 	Growth driven by price actions and continued strong performance of the ACUVUE
OASYS 1-Day family (recent launch of OASYS MAX 1-Day including MAX 1-day multifocal for Astigmatism)
• 	Surgical: 	Increase reflects continued strength of recent innovation (TECNIS Odyssey, TECNIS PureSee,
TECNIS Eyhance) and commercial execution
Vision
Adjusted operational sales2: WW 4.1%, U.S. 4.7%, Int’l 3.4%
Orthopaedics
$2,305
Surgery
$2,555
Vision
$1,369
Cardiovascular
$2,313
■ 	Reported growth 	■ 	Operational growth1
$8,541
7.3%, 	6.1%
WW sales $MM
Strong operational growth1 of 6.1% due to Cardiovascular, commercial execution, and innovation
WW 7.3%, U.S. 8.0%, Int’l 6.7%	Reported:
WW 6.1%, U.S. 8.0%, Int’l 4.1%	Operational1:
23.5%, 	22.3%
6.5%, 	4.6%
(0.3)%, 	(1.6)%
2.7%, 	1.8%
MedTech highlights – 2nd quarter 2025
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded 15

-- 15 of 25 --

%
Increase
(Decrease)
2024	2025
% to Sales	Amount	% to Sales	Amount
5.8	100.0	$22,447	100.0	$23,743	Sales to customers
11.0	30.6	6,869	32.1	7,628	Cost of products sold
3.4	69.4	15,578	67.9	16,115	Gross Profit
3.7	25.3	5,681	24.8	5,889	Selling, marketing and administrative expenses
2.2	15.3	3,440	14.8	3,516	Research and development expense
0.9	194	-	-	In-process research and development impairments
(0.6)	(125)	0.2	48	Interest (income) expense, net
2.9	653	0.5	107	Other (income) expense, net
0.0	(13)	0.3	64	Restructuring
12.9	25.6	5,748	27.3	6,491	Earnings before provision for taxes on income
(10.2)	4.7	1,062	4.0	954	Provision for taxes on income
18.2	20.9	$4,686	23.3	$5,537	Net Earnings
-
18.7	$1.93	$2.29	Net earnings per share (Diluted)
2,422.0	2,419.1	Average shares outstanding (Diluted)
18.5%	14.7%	Effective tax rate
.
Adjusted earnings before provision for taxes and net earnings1
(2.6)	37.4	$8,404	34.5	$8,188	Earnings before provision for taxes on income
(2.1)	30.5	$6,840	28.2	$6,699	Net earnings
(1.8)	$2.82	$2.77	Net earnings per share (Diluted)
18.6%	18.2%	Effective tax rate
1 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
(Unaudited; Dollar and shares in millions except per share figures)
16
2nd Quarter 2025
Condensed consolidated statement of earnings

-- 16 of 25 --

%
Increase
(Decrease)
2024	2025
Innovative Medicine % to Sales	Amount	% to Sales	Amount
4.9	100.0	$14,490	100.0	$15,202	Sales to customers
9.5	20.0	2,905	20.9	3,180	Cost of products sold
3.8	80.0	$11,585	79.1	$12,022	Gross Profit
4.7	18.4	2,665	18.3	2,789	Selling, marketing and administrative expenses
5.8	18.7	2,712	18.9	2,869	Research and development expense
(1.7)	(254)	(0.8)	(129)	Other segment items 	1
0.5	44.6	$6,462	42.7	$6,493	Adjusted segment income before tax 	2
1 	Other segment items for each reportable segment include charges related to other income and expense
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the 	company's website
(Unaudited; Dollar in millions)
Adjusted earnings before provision for taxes on income by segment
17
%
Increase
(Decrease)
2024	2025
MedTech % to Sales	Amount	% to Sales	Amount
7.3	100.0	$7,957	100.0	$8,541	Sales to customers
14.1	34.6	2,754	36.8	3,142	Cost of products sold
3.8	65.4	$5,203	63.2	$5,399	Gross Profit
7.4	33.5	2,666	33.4	2,862	Selling, marketing and administrative expenses
3.0	8.4	670	8.1	690	Research and development expense
(2.2)	(181)	(0.6)	(53)	Other segment items 	1
(7.2)	25.7	$2,048	22.2	$1,900	Adjusted segment income before tax 	2
%
Increase
(Decrease)
2024	2025
Enterprise % to Sales	Amount	% to Sales	Amount
(2.6)	37.4	$8,404	34.5	$8,188	Adjusted segment income before tax 	2
2nd Quarter 2025

-- 17 of 25 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 18 of 25 --

Capital allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Q2 2025	Dollars in billions
$19
Cash and marketable
securities
($51)	Debt
($32)	Net debt
~$6	Free cash flow1,2
Q2 2025:
$3.5B 	invested in R&D
$6.7B 	year-to-date
$3.1B 	in dividends paid
to shareholders;
$6.1B 	year-to-date
Note: Values may be rounded
1 	Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
2 	Estimated as of July 16, 2025. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
3 	Includes Intra-Cellular Therapies acquisition closed April 2, 2025
Note: Values may be rounded
Capital allocation strategy
19
~$15B3 deployed in strategic,
inorganic growth opportunities

-- 19 of 25 --

Increasing operational2 sales guidance to 4.8% and adjusted operational EPS2,4 to 7.0% (midpoints)
Comments	April 2025	July 2025
Increasing midpoint to 3.5%	2.0% - 3.0%	3.2% - 3.7%	Adjusted operational sales1,2,6
Tightening range;
Increasing midpoint by $0.9B to 4.8%
$91.6B - $92.4B
3.3% - 4.3%
$92.7B - $93.1B
4.5% - 5.0%
Operational sales2,6
Tightening range;
Increasing midpoint by $2.0B to 5.4%
Incremental FX impact of $1.1B
$91.0B - $91.8B
2.6% - 3.6%
$93.2B - $93.6B
5.1% - 5.6%
Estimated reported sales 	3,6
Maintaining	Increase of ~300 bps	Increase of ~300 bps
Adjusted pre-tax
operating margin4,5
Maintaining	$1.0 - $1.2 billion	$1.0 - $1.2 billion	Net other income4
Decreasing due to higher interest
earned on cash balances
$100 - $200 million	$0 - $100 million	Net interest expense / (income)
Increasing due to an adjustment on
global tax reserves
16.5% - 17.0%	17.0% - 17.5%	Effective tax rate4
Tightening range;
Increasing midpoint by $0.08
$10.50 - $10.70
5.2% - 7.2%
$10.63 - $10.73
6.5% - 7.5%
Adjusted EPS (operational)2,4
Tightening range;
Increasing midpoint by $0.25
Incremental FX impact of $0.17
$10.50 - $10.70
5.2% - 7.2%
$10.80 - $10.90
8.2% - 9.2%
Adjusted EPS (reported)3,4
2025 P&L guidance
1 	Non-GAAP measure; excludes acquisitions and divestitures 	4 	Non-GAAP measure; excludes intangible amortization expense and special items
2 	Non-GAAP measure; excludes the impact of translational currency 	5 	Sales less: COGS, SM&A and R&D expenses
3 	Euro Average Rate: July 2025 = $1.13; Euro Spot Rate: July 2025 = $1.17 	6 	Excludes COVID-19 Vaccine
Note: Values may be rounded 	20

-- 20 of 25 --

Innovative
Medicine
• 	Expect more pronounced impact from newly launched products as the year progresses
• 	STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy2
• 	Negative impact of Part D re-design, as a percent to sales, will be consistently applied throughout the year3
• 	Expect acceleration of newly launched products; full year impact of Shockwave acquisition
• 	Lapping of prior year quarterly comparators to be considered
• 	Normalized procedure volume and seasonality
Phasing Considerations
MedTech
• 	One-time items impacting EPS last year:
• 	Benefit of Kenvue dividend in the first two quarters
• 	Higher interest income prior to Shockwave acquisition in May
• 	Monetization of royalty rights in Q3
• 	IPR&D expense associated with NM-26 Bi-specific antibody acquisition (Q3) and V-Wave acquisition (Q4)
P&L
21
Anticipate second half operational1 sales growth higher than the first half
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Once faced with material biosimilar competition, with the additive impact of Part D re-design
3 	Products negatively impacted include STELARA, INVEGA long acting injectables, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA and IMBRUVICA, partially offset by a favorable impact in XARELTO

-- 21 of 25 --

Innovative Medicine
Anticipated 2025 milestones1 driving long-term value creation
MedTech
22
TAR-200 NMIBC
RYBREVANT Sub-Q in NSCLC
TREMFYA Sub-Q in UC
CAPLYTA in aMDD
icotrokinra in PsO and UC
TREMFYA PsA
RYBREVANT in HNC
VOLT Plating System
STSF Dual Energy
OTTAVA
IMPELLA ECP
ATTUNE Revision Hinge
ETHICON 4000 Stapler
ACUVUE OASYS MAX for Astigmatism
1 	List above is not inclusive of all 2025 anticipated milestones
Sub-Q: Subcutaneous; NSCLC: Non-small cell lung cancer; UC: Ulcerative colitis; NMIBC: Non-muscle invasive bladder cancer; PsO: Psoriasis; HNC: head and neck cancer; aMDD: Adjunctive major depressive disorder; PsA: Psoriatic arthritis; STSF: SMARTTOUCH Surround Flow

-- 22 of 25 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 23 of 25 --

Slide footer goes here if required 	24

-- 24 of 25 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
US 	SIMPONI (golimumab) 	P 	US 	IMAAVY (nipocalimab 	) 	US 	nipocalimab 	P 	US
TAR-200 (RIS/gemcitabine plus
cetrelimab) 	P 	AKEEGA (niraparib/abiraterone) 	P
TAR-200 (RIS/gemcitabine plus
cetrelimab)
EU 	Pediatric Ulcerative Colitis
(PURSUIT 2)
EU 	Generalized Myasthenia Gravis
(Vivacity MG3)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
M1 Metastatic Castration-Sensitive
Prostate Cancer (AMPLITUDE)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
STELARA (ustekinumab) 	P 	US 	SPRAVATO (esketamine) 	TREMFYA (guselkumab) 	P 	US 	AKEEGA (niraparib/abiraterone) 	P 	RYBREVANT / LAZCLUZE 	RYBREVANT (amivantamab)
P 	EU 	Pediatric Crohn's Disease (UNITI
JR)
Treatment Resistant Depression
monotherapy (TRD4005)
P 	EU 	Ulcerative Colitis Subcutaneous
Induction (ASTRO)
P 	EU 	M1 Metastatic Castration-Sensitive
Prostate Cancer (AMPLITUDE)
Non Small Cell Lung Cancer (MARIPOSA
Final OS)
Head and Neck Cancer (ORIGAMI-4)
US 	TREMFYA (guselkumab) 	US 	CAPLYTA (lumateperone) 	US 	TREMFYA (guselkumab) 	P 	TREMFYA (guselkumab) 	P 	TALVEY + TECVAYLI
Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Adjunctive Treatment for Major
Depressive Disorder
Psoriatic Arthritis Structural
Damage (APEX)
Ulcerative Colitis Subcutaneous Induction
(ASTRO)
Multiple Myeloma
Relapsed/Refractory (RedirecTT-1)
P 	US 	TREMFYA (guselkumab) 	US 	DARZALEX (daratumumab) 	TREMFYA (guselkumab) 	P 	TREMFYA (guselkumab) 	P 	JNJ-4496
P 	EU 	Crohn's Disease Subcutaneous
Induction (GRAVITI)
EU 	Smoldering Multiple Myeloma
(AQUILA)
P 	EU 	Pediatric Psoriasis
(PROTOSTAR)
Psoriatic Arthritis Structural Damage
(APEX)
Hematological Malignancies
(LYM1001)
US 	TREMFYA (guselkumab) 	US 	DARZALEX (daratumumab) 	US 	STELARA (ustekinumab) 	P 	TREMFYA (guselkumab) 	P 	JNJ-5322
Pediatric Psoriasis
(PROTOSTAR)
P 	EU 	Frontline multiple myeloma
transplant ineligible (CEPHEUS)
EU 	Pediatric Ulcerative Colitis
(UNIFI JR)
Pediatric Psoriasis (PROTOSTAR) 	Multiple Myeloma (MMY1001)
US 	TREMFYA (guselkumab) 	US
TAR-200 (RIS/gemcitabine plus
cetrelimab) 	P 	US 	STELARA (ustekinumab) 	P 	icotrokinra 	P 	RYBREVANT (amivantamab)
Pediatric Juvenile Psoriatic
Arthritis
Non Muscle Invasive Bladder
Cancer (SunRISe-1)
Pediatric Crohn's Disease (UNITI
JR)
Psoriasis (ICONIC-LEAD) 	Colorectal Cancer (ORIGAMI-1 right-
sided)
P 	US 	TREMFYA (guselkumab) 	US 	RYBREVANT (amivantamab) 	US 	icotrokinra 	P 	icotrokinra 	P 	JNJ-8343
P 	EU 	Crohn's Disease (GALAXI) 	P 	EU 	Subcutaneous (PALOMA-3) 	EU 	Psoriasis (ICONIC) 	Psoriasis (ICONIC-TOTAL) 	Prostate Cancer (PCR1001)
TREMFYA (guselkumab) 	IMBRUVICA (ibrutinib) 	icotrokinra 	JNJ-4804 Co-antibody Therapy
P 	EU 	Ulcerative Colitis (QUASAR) 	EU 	Frontline MCL (Triangle) 	Psoriasis (ICONIC-Advance1/2) 	Psoriatic Arthritis (AFFINITY)
P 	US 	IMAAVY (nipocalimab 	) 	P 	aticaprant 	icotrokinra
Generalized Myasthenia Gravis
Pediatrics (VIBRANCE MG)
Adjunctive Treatment for Major Depressive
Disorder with Anhedonia (Ventura 1)
Ulcerative Colitis (ANTHEM)
P 	RPGR Gene Therapy 	nipocalimab 	Combination Therapy
Retinitis Pigmentosa (LUMEOS) 	Rheumatoid Arthritis (DAISY)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2025*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and
does not guarantee continued investment. This information is as of July 16, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
1 	In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets
and does not guarantee continued investments. This information is as of July 16, 2025 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.
= 	Achieved

-- 25 of 25 --